Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Increases By 133.2%

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 87,000 shares, an increase of 133.2% from the October 31st total of 37,300 shares. Approximately 5.6% of the company’s shares are short sold. Based on an average daily trading volume, of 91,900 shares, the short-interest ratio is currently 0.9 days.

60 Degrees Pharmaceuticals Trading Up 7.9 %

Shares of NASDAQ SXTP traded up $0.08 on Thursday, reaching $1.09. 263,660 shares of the company traded hands, compared to its average volume of 241,440. The stock has a market capitalization of $2.51 million, a PE ratio of -0.11 and a beta of 4.78. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $18.36. The company has a 50 day moving average of $1.02 and a 200 day moving average of $0.76.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, November 15th.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.